Trial Profile
Effect of PCSK9 Inhibition on Cardiovascular Risk in Treated HIV Infection (EPIC-HIV Study)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Apr 2022
Price :
$35
*
At a glance
- Drugs Alirocumab (Primary)
- Indications Cardiovascular disorders
- Focus Therapeutic Use
- Acronyms EPIC-HIV
- 25 Apr 2022 Planned End Date changed from 1 Nov 2021 to 1 Jul 2025.
- 25 Apr 2022 Planned primary completion date changed from 1 Nov 2021 to 1 Jul 2024.
- 20 Jun 2018 Status changed from not yet recruiting to recruiting.